Compare IIPR & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIPR | BHVN |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | 23 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2022 |
| Metric | IIPR | BHVN |
|---|---|---|
| Price | $57.10 | $9.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $45.00 | $29.08 |
| AVG Volume (30 Days) | 337.2K | ★ 1.6M |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | ★ 14.28% | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.69 | N/A |
| Revenue Next Year | $3.80 | N/A |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.58 | $7.48 |
| 52 Week High | $61.40 | $18.57 |
| Indicator | IIPR | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 57.49 | 48.51 |
| Support Level | $52.47 | $9.26 |
| Resistance Level | $57.58 | $10.22 |
| Average True Range (ATR) | 2.62 | 0.71 |
| MACD | 0.37 | -0.02 |
| Stochastic Oscillator | 52.14 | 37.76 |
Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.